# A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

> **NCT03499704** · PHASE4 · COMPLETED · sponsor: **Celltrion Pharm, Inc.** · enrollment: 133 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Pioglitazone + Alogliptin
- **DRUG:** Alogliptin
- **DRUG:** Metformin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT03499704
- **Lead sponsor:** Celltrion Pharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-16
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499704, "A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03499704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*